This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations
Journal of Hematology & Oncology Open Access 13 May 2022
-
RTK-RAS pathway mutation is enriched in myeloid sarcoma
Blood Cancer Journal Open Access 23 May 2018
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937–951.
Ansari-Lari MA, Yang CF, Tinawi-Aljundi R, Cooper L, Long P, Allan RH et al. FLT3 mutations in myeloid sarcoma. Br J Haematol 2004; 126: 785–791.
Falini B, Lenze D, Hasserjian R, Coupland S, Jaehne D, Soupir C et al. Cytoplasmic mutated nucleophosmin (NPM) defines the molecular status of a significant fraction of myeloid sarcomas. Leukemia 2007; 21: 1566–1570.
Bamford S, Dawson E, Forbes S, Clements J, Pettett R, Dogan A et al. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer 2004; 91: 355–358.
Rollig C, Bornhauser M, Thiede C, Taube F, Kramer M, Mohr B et al. Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting system. J Clin Oncol 2011; 29: 2758–2765.
Dufresne A, Bertucci F, Penel N, Le Cesne A, Bui B, Tubiana-Hulin M et al. Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis. Br J Cancer 2010; 103: 482–485.
Saini M, Jha AN, Abrari A, Ali S . Expression of proto-oncogene KIT is up-regulated in subset of human meningiomas. BMC Cancer 2012; 12: 212.
Inokuchi K, Yamaguchi H, Tarusawa M, Futaki M, Hanawa H, Tanosaki S et al. Abnormality of c-kit oncoprotein in certain patients with chronic myelogenous leukemia—potential clinical significance. Leukemia 2002; 16: 170–177.
Foster R, Byrnes E, Meldrum C, Griffith R, Ross G, Upjohn E et al. Association of paediatric mastocytosis with a polymorphism resulting in an amino acid substitution (M541L) in the transmembrane domain of c-KIT. Br J Dermatol 2008; 159: 1160–1169.
Shih AH, Abdel-Wahab O, Patel JP, Levine RL . The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer 2012; 12: 599–612.
Braggio E, Egan JB, Fonseca R, Stewart AK . Lessons from next-generation sequencing analysis in hematological malignancies. Blood Cancer J 2013; 3: e127.
Cancer Genome Atlas Research N. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013; 368: 2059–2074.
Gaidzik VI, Schlenk RF, Moschny S, Becker A, Bullinger L, Corbacioglu A et al. Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group. Blood 2009; 113: 4505–4511.
Casalegno-Garduno R, Schmitt A, Schmitt M . Clinical peptide vaccination trials for leukemia patients. Expert Rev Vaccines 2011; 10: 785–799.
Acknowledgements
This work was funded by the American Cancer Society Institutional Research Grant (#IRG-58-004) and the University of Chicago Comprehensive Cancer Center Support Grant (#P30 CA14599).
Author Contributions
ZL, MS, MKM, KLY and OB performed the experiments. FS, RL, WS and KO contributed patient samples and clinical data. ZL, MS, FS, KO, LJ and GR analyzed and interpreted the data. ZL, FS, KO and GR wrote the paper. GR designed and coordinated the research study.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Leukemia website
Supplementary information
Rights and permissions
About this article
Cite this article
Li, Z., Stölzel, F., Onel, K. et al. Next-generation sequencing reveals clinically actionable molecular markers in myeloid sarcoma. Leukemia 29, 2113–2116 (2015). https://doi.org/10.1038/leu.2015.81
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2015.81
This article is cited by
-
Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations
Journal of Hematology & Oncology (2022)
-
Progression, transformation, and unusual manifestations of myelodysplastic syndromes and myelodysplastic-myeloproliferative neoplasms: lessons learned from the XIV European Bone Marrow Working Group Course 2019
Annals of Hematology (2021)
-
RTK-RAS pathway mutation is enriched in myeloid sarcoma
Blood Cancer Journal (2018)
-
Mutational profiling of isolated myeloid sarcomas and utility of serum 2HG as biomarker of IDH1/2 mutations
Leukemia (2018)